Quarterly ResultMay 7, 2026, 04:30 PM
Aligos Therapeutics Q1 Net Loss $23.04M; Going Concern Doubt
AI Summary
Aligos Therapeutics reported a net loss of $23.04 million for Q1 2026, a significant decline from a net income of $43.09 million in Q1 2025. The company's cash, cash equivalents, and short-term investments totaled $54.9 million as of March 31, 2026, which is expected to fund operations only into Q4 2026, raising substantial doubt about its ability to continue as a going concern. Revenue from customers increased to $2.83 million from $0.31 million year-over-year.
Key Highlights
- Net loss of $23.04 million for Q1 2026, compared to net income of $43.09 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $54.9 million as of March 31, 2026.
- Company expects current funds to last only into Q4 2026, raising substantial doubt about its going concern ability.
- Revenue from customers increased to $2.83 million in Q1 2026 from $0.31 million in Q1 2025.
- Loss from operations increased to $26.93 million in Q1 2026 from $19.24 million in Q1 2025.
- Net cash used in operating activities was $23.13 million in Q1 2026, up from $20.91 million in Q1 2025.
- Accumulated deficit grew to $665.2 million as of March 31, 2026.